25 completed, 4 active not recruiting, 2 recruiting, 2 terminated. 35 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 25, Active not recruiting 4, Recruiting 2, Terminated 2, Withdrawn 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Short Bowel Syndrome: new trials by email Literature Review of Short Bowel Syndrome trials Research Report on Short Bowel Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) Apraglutide, Placebo - Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF) | Phase 3 | Recruiting | VectivBio AG | 124 | 2026-08-01 | 2026-08-04 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Recruiting | Zealand Pharma | 90 | 2026-02-11 | 2026-09-29 |
| Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome Glepaglutide 10 mg - Short Bowel Syndrome (SBS) | Phase 3 | Active not recruiting | Zealand Pharma | 28 | 2025-12-11 | 2026-07-30 |
| A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome Teduglutide - Short Bowel Syndrome | Phase 3 | Active not recruiting | Takeda | 13 | 2025-06-26 | 2026-09-08 |
| Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition PJ009, PJ009 Placebo - Short Bowel Syndrome | Phase 3 | Active not recruiting | Chongqing Peg-Bio Biopharm Co., Ltd. | 72 | 2024-09-03 | 2026-10-22 |
| A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older Teduglutide - Short Bowel Syndrome | Phase 3 | Completed | Takeda | 3 | 2022-01-04 | 2024-05-16 |
| The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome Glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 12 | 2021-08-10 | 2024-11-22 |
| Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. Apraglutide - Short Bowel Syndrome | Phase 3 | Active not recruiting | VectivBio AG | 158 | 2021-07-13 | 2025-07-02 |
| Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial Glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 84 | 2021-06-16 | 2026-09-08 |
| Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF apraglutide - Short Bowel Syndrome | Phase 3 | Completed | VectivBio AG | 164 | 2021-01-26 | 2024-11-27 |
| Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 150 | 2019-05-07 | 2026-09-08 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 106 | 2018-10-04 | 2025-07-17 |
| Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Teduglutide, Standard Medical Therapy, Syringe - Short Bowel Syndrome | Phase 3 | Completed | Shire | 10 | 2018-08-31 | 2021-05-11 |
| An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 Teduglutide, Syringe, Needle - Short Bowel Syndrome | Phase 3 | Completed | Takeda | 11 | 2018-07-09 | 2023-03-15 |
| Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Teduglutide, Syringe, Needle - Short Bowel Syndrome | Phase 3 | Completed | Shire | 7 | 2018-07-06 | 2020-08-04 |
| A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302 Teduglutide - Short Bowel Syndrome | Phase 3 | Completed | Shire | 9 | 2017-08-23 | 2022-05-24 |
| Safety and Efficacy Study in Infant With SBS NTRA-9620, Placebo - Short Bowel Syndrome | Phase 2 / Phase 3 | Terminated | Elgan Pharma Ltd. | 2 | 2017-03-20 | 2021-10-12 |
| Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support Teduglutide - Short Bowel Syndrome | Phase 3 | Completed | Shire | 10 | 2017-01-13 | 2022-02-02 |
| Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) TED, SOC, Syringe - Short Bowel Syndrome | Phase 3 | Completed | Shire | 61 | 2017-01-09 | 2025-03-28 |
| Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study Teduglutide, SOC - Short Bowel Syndrome | Phase 3 | Completed | Shire | 29 | 2016-12-09 | 2025-03-19 |
Showing 20 of 35. Sign in to see all of them.
Hyperphagia (6) · Intestinal Failure (4) · Cholestasis (3) · Gastrointestinal Diseases (3) · Digestive System Diseases (2) · Intestinal Diseases (2) · Malabsorption Syndromes (2) · Pathologic Processes (2) · Postoperative Complications (2) · Colitis, Ulcerative (1) · Gastroschisis (1) · Infant, Premature, Diseases (1) · Intestinal Atresia (1) · Pathological Conditions, Signs and Symptoms (1)
Pathological Conditions, Signs and Symptoms (34) · Digestive System Diseases (33) · Intestinal Diseases (33) · Malabsorption Syndromes (33) · Pathologic Processes (33) · Postoperative Complications (33) · Gastrointestinal Diseases (32) · Signs and Symptoms (6) · Signs and Symptoms, Digestive (6) · Bile Duct Diseases (3) · Biliary Tract Diseases (3) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Colitis (1) · Colonic Diseases (1)
teduglutide (16) · ALX-0600 (6) · Needles (4) · Syringes (4) · apraglutide (3) · fish oil triglycerides (3) · Glucagon-Like Peptide 2 (1) · Loperamide (1) · Standard of Care (1)
Shire (14) · Zealand Pharma (6) · Takeda (3) · VectivBio AG (3) · Marathon Pharmaceuticals, LLC (2) · Chongqing Peg-Bio Biopharm Co., Ltd. (1) · Elgan Pharma Ltd. (1) · Hospices Civils de Lyon (1) · Kapiolani Medical Center For Women & Children (1) · Mark Puder (1) · Odense University Hospital (1) · University of Oklahoma (1)
United States (23) · United Kingdom (16) · France (14) · Denmark (13) · Belgium (12) · Germany (12) · Poland (12) · Canada (10) · Italy (9) · Japan (9) · Netherlands (8) · Spain (6) · Finland (4) · Hungary (4) · Argentina (3)
Tomasz Masior (2) · Huanlong Qin (1) · Kimberly D Ernst, MD, MSMI (1) · Lynn M Iwamoto, MD (1) · Niels Qvist, MD, DMsc (1)
PMID 37364133, PMID 21317170, PMID 24134154, PMID 27507402, PMID 37889619, PMID 38873891, PMID 41858082, PMID 16099790, PMID 19661785, PMID 21975668, PMID 22982184, PMID 23274148, PMID 23333663, PMID 23587733, PMID 27855998, PMID 28627732, PMID 29174926, PMID 29761915, PMID 31784300, PMID 32059815, PMID 32341691, PMID 33038344, PMID 34695449, PMID 39708985, PMID 41454663
2004 (2), 2016 (2), 2008 (1), 2009 (1), 2017 (1), 2025 (1)